Advertisement
Tim Dietlin, Vice President, will lead a workshop that examines bestpractices for accelerated study start-up, and Gary Tyson, Senior VicePresident, will conduct a workshop that will explore strategies for becomingthe sponsor of choice for clinical investigators. In addition to the CampbellAlliance executives leading these sessions, three industry executives willserve on the panel at each of the two workshops.
Advertisement
Mr. Dietlin's workshop, titled "The Keys to Establishing Best Practicesfor Accelerated Study Start-Up," will be conducted on Monday, June 23 from3:30 pm to 5:00 pm. The workshop, which is part of the Clinical Research andDevelopment track, will examine best practices and methods for developing astudy start-up framework, such as conducting an upfront assessment of anorganization's current environment and approaches to study start-up,evaluating the steps that can be taken to streamline operations, anddeveloping training requirements and materials to integrate the framework intodaily start-up activities.
"The speed of clinical study start-up can affect an entire clinical trial,and the study team has only one shot at getting it right," Mr. Dietlin said."Overall success or failure is typically determined well before start-up, soproper planning and management is critical, especially given theever-increasing complexity of managing the range of activities involved instart-up including technology requirements, site requirements, and generalstudy management."
Mr. Dietlin brings extensive management consulting experience to CampbellAlliance as a Vice President in the Clinical Development practice. Hespecializes in helping clients improve their clinical development operationsand business processes to optimize the flow of critical information, increasethe efficacy of key processes, and enhance organizational capabilities. Mr.Dietlin earned his MBA from DePaul University's Kellstadt Graduate School ofBusiness and has a BA from Loyola University of Chicago.
On the day after Mr. Dietlin's workshop, Tuesday, June 24, Mr. Tyson willconduct a workshop titled "Becoming a Sponsor of Choice for ClinicalInvestigators" from 8:00 am to 9:30 am. The workshop, which is part of theClinical Trial Management/Clinical Supplies track, will discuss key factorsdriving investigators' choices of clinical study sponsors. It will alsoexplore tactics for identifying a pharmaceutical or biotech company'sstrengths and weaknesses with respect to conducting clinical trials, as wellas examine strategies for improving a company's relationship with the studysites and investigators it values most.
"It's critical that a pharmaceutical company do everything it can to bethe study sponsor that sites prefer to work with -- the sponsor of choice --because there are so many clinical trials that are competing for the samepatients," Mr. Tyson said. "Companies will gain a clear advantage if theyunderstand what's behind an investigator's or study site's decision to workwith a particular sponsor," he said.
As the head of Campbell Alliance's Clinical Development Practice, Mr.Tyson leads a team that provides a range of operational improvement servicesto clinical development organizations within pharmaceutical and biotechcompanies, as well as at leading contract research organizations (CROs). Heis a veteran of numerous electronic-data-capture-related initiatives, andbrings a wealth of knowledge and experience in process improvement,organizational design, and clinical development to his consulting engagement
